We utilize advanced co-culture systems to simulate complex interactions between tumor cells and the immune system, providing deep mechanistic insights into therapeutic activation, immune evasion, and cell-mediated cytotoxicity.
Learn More →With the rapid progress of various immunotherapies, especially therapeutic antibodies, the discovery and development of potential anticancer immunotherapy approaches have become a promising direction. Creative Biolabs is dedicated to offering a comprehensive set of standalone or integrated services to support preclinical testing, including in vivo pharmacology, drug metabolism and pharmacokinetics, toxicology, and efficacy models.
Even though many cancer immunotherapies offer fresh hope for cancer patients, only a small portion of cancer patients can be cured by immunotherapies. New immunotherapies need to be explored urgently. For a potential drug candidate, safety and efficacy data need to be evaluated before exposure to humans. To assess the antitumor efficacy in animal models, specific oncology efficacy models need to be established.
Partner with Creative Biolabs to ensure your preclinical data is truly predictive - Request a consultation.
Fig.1 Integrating advanced efficacy models to address tumor microenvironment heterogeneity. 1
As an end-to-end solution provider and concentrated CRO in cancer immunotherapy discovery and development, Creative Biolabs offers a comprehensive suite of validated oncology in vivo models for our clients to advance their preclinical development projects in a cost-effective and timely manner. We are committed to helping you choose the most appropriate efficacy model, design studies, and screen assays matched to your drug candidates, including checkpoint inhibitors, co-stimulatory agonists, viruses, therapeutic engineered immune cells, cytokines, and antibodies.
We utilize advanced co-culture systems to simulate complex interactions between tumor cells and the immune system, providing deep mechanistic insights into therapeutic activation, immune evasion, and cell-mediated cytotoxicity.
Learn More →These are specialized models essential for evaluating agents that target the immune system to fight cancer. They include syngeneic and human immune component models, focusing on the dynamic interplay between the drug, the tumor, and immune effector cells.
Learn More →Utilize immunocompetent murine host mice and mouse-derived tumor cells. They are fast, cost-effective, and possess an intact, fully functional murine immune system, making them essential for initial T-cell engager, checkpoint inhibitor, and vaccine evaluations.
Learn More →These models are reconstituted with human hematopoietic stem cells or peripheral blood mononuclear cells (PBMCs), resulting in functional, mature human immune system components (T cells, B cells, NK cells).
Learn More →Involve transplanting established human cancer cell lines into immunodeficient mice. They offer fast, highly reproducible, and cost-effective initial efficacy screening and single-target MOA confirmation, serving as a reliable foundational screen for many compounds.
Learn More →Creative Biolabs maintains an extensive, validated database of hundreds of CDX models spanning multiple cancer types, each meticulously characterized for genetic mutations (e.g., BRAF, KRAS, EGFR) and protein expression.
Learn More →These models involve the direct transplantation of tumor tissue fragments from a source into immunodeficient mice. PDX models meticulously maintain the original tumor's genomic, histological, and molecular characteristics and tumor heterogeneity.
Learn More →We establish personalized 3D cancer models from specific patient tissues, providing a clinically relevant platform to evaluate therapeutic efficacy and drug response within a biomimetic, patient-specific environment.
Learn More →Specialized human immune component models focused on the function of dendritic cells (DCs). These are utilized for targeted in vivo testing of therapeutics designed to modulate or exploit the DC population for enhanced anti-tumor immunity.
Learn More →Custom models designed to assess therapeutic agents that modulate macrophage function. These are essential for evaluating agents whose efficacy relies on reprogramming the tumor microenvironment (TME) or leveraging phagocytosis (ADCP).
Learn More →
| Our Advantages | Key Features |
|---|---|
| Extensive Model Inventory | Access an expansive, characterized repository encompassing over fifty diverse human cancer cell lines for xenograft models, facilitating precise screening against a wide array of disease characteristics. |
| High Data Fidelity | Our studies utilize rigorous quality control protocols and validated model systems to consistently generate highly reproducible and accurate efficacy data, accelerating your research progression. |
| Quality Assurance Expertise | Receive specialized consultation from experts, ensuring that the study design and data generation processes adhere to the highest internal quality standards for seamless compound development. |
Our strategy team is standing by to discuss your specific project needs and help you select the ideal efficacy model system. - Get a quote today.
Our PDX models are sourced and maintained to preserve the tumor's original heterogeneity, stroma, and complex architecture - features often lost in long-term cell lines. This better recapitulation of the tumor microenvironment means that efficacy data is far more relevant to compound outcomes. We encourage you to discuss your specific tumor type with our preclinical strategy team for tailored PDX options.
You will receive a fully integrated package, including detailed tumor volume and survival curves, full-color histology slides, and comprehensive molecular data (e.g., flow cytometry results on immune cell infiltration, and spatial transcriptomics analysis). This integrated approach answers not just if the drug works, but how and why, providing the evidence needed for advancing compound development.
With extensive experience and expertise, Creative Biolabs has established comprehensive efficacy models to facilitate in vivo efficacy evaluation for new potential immunotherapeutic. Please don't hesitate to contact us for our experts' advice about choosing the appropriate efficacy model to best fit your needs.
Reference